Vor Biopharma (NYSE:VOR) Earns "Outperform" Rating from Wedbush

Vor Biopharma (NYSE:VOR - Get Free Report)'s stock had its "outperform" rating reissued by Wedbush in a research note issued on Thursday,RTT News reports. They presently have a $7.00 price target on the stock.

Several other equities research analysts have also issued reports on VOR. HC Wainwright restated a "buy" rating and set a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. JMP Securities reissued a "market outperform" rating and issued a $12.00 target price on shares of Vor Biopharma in a research report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vor Biopharma presently has an average rating of "Buy" and a consensus price target of $8.86.

Vor Biopharma Price Performance

Shares of Vor Biopharma stock traded up $0.01 during trading hours on Thursday, hitting $0.88. 210,327 shares of the company's stock traded hands, compared to its average volume of 590,640. The stock has a market capitalization of $60.74 million, a price-to-earnings ratio of -0.54 and a beta of -0.40. Vor Biopharma has a 12-month low of $0.63 and a 12-month high of $2.43. The company has a fifty day simple moving average of $1.22 and a 200-day simple moving average of $1.01.

Institutional Trading of Vor Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of VOR. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in shares of Vor Biopharma during the 4th quarter valued at $33,000. Virtu Financial LLC purchased a new position in Vor Biopharma during the fourth quarter worth about $60,000. XTX Topco Ltd bought a new position in Vor Biopharma in the 4th quarter worth about $80,000. Trustees of Columbia University in the City of New York purchased a new stake in shares of Vor Biopharma in the 4th quarter valued at about $102,000. Finally, Northern Trust Corp boosted its position in shares of Vor Biopharma by 39.0% during the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after acquiring an additional 44,252 shares during the last quarter. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.